Disclaimer: Views in this blog do not promote, and are not directly connected to any Legal & General Investment Management (LGIM) product or service. Views are from a range of LGIM investment professionals and do not necessarily reflect the views of LGIM. For investment professionals only.
Podcast: How the market made a home for orphan drugs
Our latest Blog on the Pod episode examines the market for 'orphan drugs', which target rare diseases.
Innovative treatments are needed for those affected by rare conditions, but how do the economics stack up given the huge costs involved? Elisa Piscopiello, ETF Analyst at LGIM, explains how government incentives are helping to finance the development of life-changing medicines.
This podcast is hosted by Harry Brooks, Content Manager.
You can listen on Apple, Audioboom and Spotify.
All data is from Eikon as at 28 February 2023 unless otherwise stated.
For professional investors only. Capital at risk.
Recommended content for you
Learn more about our business
Legal & General Investment Management is one of the world's largest asset managers, with capabilities across asset classes to meet our clients' objectives and a longstanding commitment to responsible investing.
